OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.81 EUR 3.57% Market Closed
Market Cap: 127.5m EUR

OSE Immunotherapeutics SA
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Pre-Tax Income
€49.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Pre-Tax Income
-€11.5m
CAGR 3-Years
45%
CAGR 5-Years
-68%
CAGR 10-Years
8%
Nanobiotix SA
PAR:NANO
Pre-Tax Income
-€33.2m
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
-15%
G
Genfit SA
PAR:GNFT
Pre-Tax Income
€22.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Pre-Tax Income
-€183.6m
CAGR 3-Years
-55%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Pre-Tax Income
€10m
CAGR 3-Years
-54%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

OSE Immunotherapeutics SA
Glance View

Market Cap
126.4m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
7.9 EUR
Undervaluation 26%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Pre-Tax Income?
Pre-Tax Income
49.4m EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Pre-Tax Income amounts to 49.4m EUR.

Back to Top